What Happened

GSK is cutting more than 1,200 roles across its Belgium sites — Rixensart, Wavre and Gembloux — as part of a $2.5 billion global restructuring announced in July 2026. The company confirmed to BioSpace that the reductions could affect up to 1,217 employees and are intended to streamline research, manufacturing and support operations, in part through digital and automation tools.

Who Is Affected

The layoffs will impact roles across GSK's research, manufacturing and support functions at the three Belgian sites. Even after the cuts, GSK stated it will remain the largest biopharma employer in Belgium, with the country serving as a major hub for vaccines manufacturing, contributing over 50% of the company's global vaccine operations.

Market Impact

• Vaccine revenue remains strong: GSK's second-quarter 2026 vaccine sales grew 8% year-on-year, driven by Shingrix (£900M) and Arexvy (surged >100% to £200M).
• Restructuring funds pipeline: The $2.5B savings plan is designed to keep capital flowing into the late-stage portfolio, including an mRNA seasonal flu vaccine now in Phase 3.
• Automation opportunity: The company explicitly cited digital tools and automation in streamlining operations — a direct entry point for HR tech, outplacement and R&D tooling vendors.

What to Watch

Implementing the restructuring will play out over three years. Expect further global job cuts beyond Belgium, as the company consolidates manufacturing (e.g., shutting a German site). Vaccine manufacturing output at the Belgian hub and pipeline progression will be key indicators of how the reshaping affects the broader biopharma landscape.

Related coverage

• GSK pledges $800M to add biologics production capabilities in Pennsylvania
• Enanta Pharmaceuticals lays off 37 employees ahead of key antiviral and immunology readouts
• Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
• BioNTech to close 3 German sites after failed buyer search, ~1,800 jobs impacted